The IP & Science business of Thomson Reuters has announced a series of industry-first milestones in its Cortellis platform. Cortellis, the premier source of life sciences competitive intelligence information and analytics, has reached new content milestones with more than 50,000 investigational drugs, 400,000 bioactive compounds, and six million biologically active patents. In total, the solution contains over 15 million expert, human-curated reports featuring deal information, patents, literature and clinical trials data.
The Cortellis milestones are in addition to new data being integrated into the platform as a result of three recent acquisitions. These include Deloitte Recap, the leading biopharmaceutical provider of life science deals, acquisitions data and analytics; BioWorld and Medical Device Daily, premiere daily news sources in the biopharma and medical device industries; and Timely Data Resources, the esteemed provider of epidemiology information for biopharmaceutical companies, device manufacturers, universities and research institutions.
Thomson Reuters employs a rigorous review process for each investigational drug featured in Cortellis. The editorial team combs through two-to-three years' worth of information, compiling a unique profile that includes basic drug information as well as recent news articles, publications, events, and more. Users benefit from an all-in-one-place summary of the compound, without having to spend days researching and parsing information on their own.
Reports on trials, literature, patents and deals are also manually curated and revised daily by industry experts to ensure they contain the most up-to-date competitive intelligence from over 40,000 sources. In addition to providing sophisticated analytics and visualizations within Cortellis, the platform also has an open architecture that allows information to be easily incorporated into other software solutions and customer workflows to enable faster decision making.
